Celltrion Inc (068270) Stock Price & News

068270:KRX

Celltrion Inc

₩188,100.00

+0.53%

(+1,000.00) 1D

Sep 4, 3:30:03 PM GMT+9 · KRW

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Generating top insights for 068270...

Open

₩189,000

High

₩189,100

Low

₩186,600

Mkt. cap

43.76T

Avg. vol.

642.66K

Volume

270.58K

Dividend

0.38%

Quarterly dividend

₩179

Ex-dividend date

Dec 29, 2025

P/E ratio

27.49

52-wk high

₩239,047

52-wk low

₩158,500

EPS

₩6,842

Shares outstanding

232.62M

No. of employees

Open

₩189,000

High

₩189,100

Low

₩186,600

Mkt. cap

43.76T

Avg. vol.

642.66K

Volume

270.58K

Dividend

0.38%

Quarterly dividend

₩179

Ex-dividend date

Dec 29, 2025

P/E ratio

27.49

52-wk high

₩239,047

52-wk low

₩158,500

EPS

₩6,842

Shares outstanding

232.62M

No. of employees

Related stocks

Samsung Biologics Co Ltd

₩1,447,000.00

-2.03%

005930

Samsung Electronics Co Ltd

Profile

Celltrion, Inc. is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea. Seo Jung-jin, its founder was awarded the 2021 EY World Entrepreneur Of The Year. Wikipedia

About Celltrion Inc

CEOWoosung Kee

Employees2.96K

Founded2002

Headquarters-

SectorBiotechnology

Websitecelltrion.com

All values in KRW	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	1.03T	1.33T	1.14T	1.39T
Cost of goods sold	402.86B	476.46B	459.14B	529.46B
Cost of revenue	402.86B	476.46B	459.14B	529.46B
Research and development expenses	-	210.70B	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	324.69B	3.23B	363.97B	412.44B
Operating expense	324.69B	383.06B	363.97B	412.44B
Total operating expenses	727.56B	859.52B	823.12B	941.90B
Operating income	301.41B	470.64B	321.87B	451.79B
Other non operating income	-17.89B	1.02B	-6.34B	-8.26B
EBT including unusual items	377.94B	527.86B	432.20B	457.77B
EBT excluding unusual items	378.19B	528.09B	432.23B	456.52B
Income tax expense	46.02B	-64.71M	82.35B	86.45B
Effective tax rate	12.18%	-0.01%	19.05%	18.89%
Other operating expenses	-	93.27B	-	-
Net income	331.35B	528.43B	346.14B	370.20B
Net profit margin	32.20%	39.73%	30.23%	26.56%
Earnings per share	1.44K	2.28K	1.50K	1.61K
Interest and investment income	4.75B	5.40B	6.19B	9.78B
Interest expense	-18.08B	-21.35B	-26.72B	-27.78B
Net interest expenses	-13.34B	-15.95B	-20.53B	-18.00B
Depreciation and amortization charges	-	17.16B	-	-
EBITDA	374.56B	537.36B	398.40B	528.71B
Gain or loss from assets sale	-150.99M	16.25M	5.84M	-1.25B

Finance

Ask anything